Health Innovation Next Generation Payment & Pricing Models

Información del proyecto

HI-PRIX

Identificador del acuerdo de subvención: 101095593

DOI

10.3030/101095593

Proyecto cerrado

Fecha de la firma de la CE 11 Noviembre 2022

Fecha de inicio 1 Enero 2023

Fecha de finalización 31 Diciembre 2025

Financiado con arreglo a

• Health

Coste total

€ 3 962 457,50

Aportación de la UE

€ 3 962 457,50

Coordinado por

UNIVERSITA COMMERCIALE LUIGI BOCCONI
Italy

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (13)

Recommendations on pricing principles for multi-indication products and conditions for their successful implementation
A novel dynamic pricing model that links to clinical benefit: impact and acceptability for stakeholders
Strength of incentive mechanisms and policy recommendations to incentivize pharmaceutical innovation in key areas of need
Equity implications of including indirect medical costs and environmental impacts in economic evaluations informing pricing and reimbursement
Policy guide on the role of cost-effectiveness and budget impact analyses (including indirect medical costs and environmental impacts) in pricing and reimbursement decisions in different European decision contexts
Outline of the equity-issues mitigation strategies identified, and related potential obstacles
Stakeholders judgement on barriers and enablers of novel payment/pricing schemes
Effectiveness and equity implications of selected pharmaceutical innovation policies and incentive mechanisms
Guidance (Handbook) on estimations (ranges) of cost elements along the value chain for demanding detailed information in price negotiations
Report on the overall performance of a selection of equity-issues mitigation strategies and recommendations
Set of recommendations for using the public investment in the negotiation/HTA process and pilot example how price can be different if public investment is considered
Policy recommendations about successful and flexible implementation of the different schemes to promote access to high-quality affordable innovative health technologies
Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on lo

Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on long-term competition in health technology markets

Demonstrators, pilots, prototypes (2)

Assessment of transferability and generalizability of results and development of a toolkit for decision-makers
Impact of applying the new payment schemes to (a) a primary care and (b) an integrated care setting

Websites, patent fillings, videos etc. (1)

Launch of project website

Publicaciones

Peer reviewed articles (18)

Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes

Autores: Baptiste Haon, Mira Hartmann, Sanae Akodad, Hilde Stevens, Lise Rochaix
Publicado en: Frontiers in Medical Technology, Edición 8, 2026, ISSN 2673-3129
Editor: Frontiers Media SA
DOI: 10.3389/FMEDT.2026.1729631

Journal of Pharmaceutical Policy and Practice

Autores: Louise Schmidt; Ozren Sehic; Ursula Theuretzbacher; Daniel Fabian; Claudia Wild
Publicado en: Journal of Pharmaceutical Policy and Practice, 2025, ISSN 2052-3211
Editor: Taylor & Francis
DOI: 10.1080/20523211.2024.2449045

AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen

Autores: Ozren Sehic
Publicado en: QUALITAS, 2024, ISSN 2730-7298
Editor: Springer Nature
DOI: 10.1007/S43831-024-0187-6

Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review

Autores: Mario García-Díaz; Zuzana Špacírová; Leticia García-Mochón; Jaime Espín
Publicado en: Applied Health Economics and Health Policy, 2025, ISSN 2509-4254
Editor: Springer Nature
DOI: 10.1007/S40258-025-00994-5

Frontiers in Psychiatry

Autores: Sanae Akodad, Michel Goldman, Hilde Stevens
Publicado en: Frontiers in Medicine, Edición 12, 2025, ISSN 1664-0640
Editor: Frontiers Research Foundation
DOI: 10.3389/FMED.2025.1642882

Applied Health Economics and Health Policy

Autores: Ludovico Cavallaro; Vittoria Ardito; Michael Drummond; Oriana Ciani
Publicado en: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Editor: Open Mind Journals
DOI: 10.1007/S40258-025-00963-Y

Health Policy

Autores: Claudia Wild; Ozren Sehic; Louise Schmidt; Daniel Fabian
Publicado en: Health Policy, 2025, ISSN 0168-8510
Editor: Elsevier Ltd.
DOI: 10.1016/J.HEALTHPOL.2024.105235

Frontiers in Pharmacology

Autores: García Díaz, Mario; Epstein, David Mark; Espín, Jaime
Publicado en: Frontiers in Pharmacology, 2025, ISSN 1663-9812
Editor: Frontiers Media SA
DOI: 10.3389/FPHAR.2025.1670845

Social Science and Medicine

Autores: Arianna Gentilini; Marisa Miraldo
Publicado en: Social Science & Medicine, 2023, ISSN 0277-9536
Editor: Pergamon Press Ltd.
DOI: 10.1016/J.SOCSCIMED.2023.116332

Orphan medical devices: addressing the regulatory and access gaps in the EU and US

Autores: Sanae Akodad; Baptiste Haon; Lise Rochaix; Hilde Stevens
Publicado en: Frontiers in Public Health, 2026, ISSN 2296-2565
Editor: Frontiers Media SA
DOI: 10.3389/FPUBH.2025.1729821

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs

Autores: Mario García-Díaz; Jorge Mestre-Ferrándiz; Jaime Espín
Publicado en: PharmacoEconomics - Open, 2026, ISSN 2509-4262
Editor: Springer Nature
DOI: 10.1007/S41669-025-00628-5

PharmacoEconomics

Autores: Vittoria Ardito; Oriana Ciani; Michael Drummond
Publicado en: PharmacoEconomics, 2024, ISSN 1179-2027
Editor: Adis International Ltd.
DOI: 10.1007/S40273-024-01435-2

Applied Health Economics and Health Policy

Autores: Ardito, Vittoria; Banks, Helen; Tarricone, Rosanna
Publicado en: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Editor: Springer Nature
DOI: 10.1007/S40258-025-01010-6

Journal of Pharmaceutical Policy and Practice

Autores: Daniel Fabian; Ozren Sehic; Claudia Wild
Publicado en: The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions, 2025, ISSN 2052-3211
Editor: Taylor & Francis Group
DOI: 10.1080/20523211.2025.2534919

Medicare Negotiations Could Fuel, Not Stifle, Innovation.

Autores: Chuanzi Yue, Marisa Miraldo
Publicado en: Health Affairs Forefront, 2025, ISSN 3070-667X
Editor: Health Affairs Publishing, LLC
DOI: 10.1377/FOREFRONT.20250116.482319

A Framework for Considering the Role of the Public Sector in R&D of Health Technology

Autores: Juan Carlos Rejon-Parrilla; David Epstein; Jorge Mestre-Ferrandiz; Jaime Espin
Publicado en: Pharmaceutical Medicine, 2025, ISSN 0306-3747
Editor: Springer Nature
DOI: 10.1007/S40290-025-00576-9

Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review

Autores: ARDITO, VITTORIA; CAVALLARO, LUDOVICO; DRUMMOND, MICHAEL; CIANI, ORIANA
Publicado en: PharmacoEconomics - Open, 2024, ISSN 2509-4254
Editor: Springer Nature
DOI: 10.1007/S41669-024-00496-5

ESG Performance, Debt Financing, and R&D Output: Evidence From the Healthcare Sector

Autores: Sarmad Ali; Oriana Ciani; Simone Ghislandi
Publicado en: Business Strategy and the Environment, ISSN 1099-0836
Editor: John Wiley & Sons Ltd
DOI: 10.1002/BSE.70522